Ramipril Capsule
Product Images NDC 71335-1056

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Ramipril (NDC 71335-1056). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713351056)

This is medication information for Ramipril 2.5mg. The medication is in the form of an orange capsule with the label "D;06" and is manufactured by Aurobindo Pharma Limited. The medication should be stored at room temperature, 20-25°C (68°-77°F), and should be kept out of reach of children. The prescription comes with 30 capsules, and the expiration date is not listed in the text. It also contains some other information like a product code and the name of the pharmacy.*

FDA Label Image

Figure 1 (Ramipril Fig1)

This appears to be a graph or chart showing the proportion of patients over time while taking the drug Ramipril. The X-axis is labeled as "Days of Follow-up", while the Y-axis appears to be showing proportions represented as numbers. Additionally, the graph includes a line labeled "P=0.0001". Without further context or a clear image, it is not possible to provide a more specific description or interpretation.*

FDA Label Image

Figure 2 (Ramipril Fig2)

This is a table with information about a medical trial involving patients with or without different diseases and risk factors. The trial studied the incidence of a composite outcome in a placebo group and the relative risk in a Ramipril group. The table shows the number of patients and the presence or absence of cardiovascular disease, diabetes, hypertension, history of coronary artery disease, prior myocardial infarction, cerebrovascular disease, peripheral vascular disease, and microalbuminuria. It also shows the incidence of the composite outcome in the placebo group and the relative risk in the Ramipril group with a 95% confidence interval.*

FDA Label Image

Chemical Structure (Ramipril Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.